

Moniek P M De Maat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1316570/publications.pdf>

Version: 2024-02-01

110
papers

3,195
citations

186265

28
h-index

168389

53
g-index

115
all docs

115
docs citations

115
times ranked

5457
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study. <i>Clinical Research in Cardiology</i> , 2022, 111, 96-104.	3.3	7
2	Platelet-dependent signaling and Low Molecular Weight Protein Tyrosine Phosphatase expression promote aggressive phenotypic changes in gastrointestinal cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166280.	3.8	3
3	Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 145-152.	2.8	9
4	Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 407-413.	1.3	3
5	Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1331-1349.	3.8	12
6	Reduced fibrin clot lysis in Klinefelter syndrome associated with hypogonadism. <i>Endocrine Connections</i> , 2022, , .	1.9	0
7	Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID-19, not entirely explaining the increased risk of thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1412-1420.	3.8	8
8	Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?. <i>Haemophilia</i> , 2022, , .	2.1	2
9	Anti-PPF4 testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1875-1879.	3.8	6
10	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2001-2011.	3.8	6
11	Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12725.	2.3	9
12	Association between plaque vulnerability and neutrophil extracellular traps (NETs) levels: The Plaque At RISK study. <i>PLoS ONE</i> , 2022, 17, e0269805.	2.5	5
13	Interaction of von Willebrand factor with blood cells in flow models: a systematic review. <i>Blood Advances</i> , 2022, 6, 3979-3990.	5.2	3
14	Biomarker association with cardiovascular disease and mortality – The role of fibrinogen. A report from the NHANES study. <i>Thrombosis Research</i> , 2021, 198, 182-189.	1.7	11
15	International Council for Standardization in Haematology (ICSH) laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: Instrument-specific issues and commonly used coagulation screening tests. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 169-183.	1.3	9
16	Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 719-731.	3.8	5
17	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. <i>HemaSphere</i> , 2021, 5, e542.	2.7	5
18	Common and Rare Variants Genetic Association Analysis of Circulating Neutrophil Extracellular Traps. <i>Frontiers in Immunology</i> , 2021, 12, 615527.	4.8	8

#	ARTICLE	IF	CITATIONS
19	International Council for Standardization in Haematology (ICSH) laboratory guidance for the verification of haemostasis analyser reagent test systems. Part 2: Specialist tests and calibrated assays. International Journal of Laboratory Hematology, 2021, 43, 907-916.	1.3	11
20	Outcome of Surgical Interventions and Deliveries in Patients with Bleeding of Unknown Cause: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1409-1416.	3.4	7
21	Thrombin generation is associated with ischemic stroke at a young age. Thrombosis Research, 2021, 202, 139-144.	1.7	6
22	Clinical value of early viscoelastometric point-of-care testing during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. Acta Obstetrica Et Gynecologica Scandinavica, 2021, 100, 1656-1664.	2.8	14
23	Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12553.	2.3	9
24	Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation. Scientific Reports, 2021, 11, 15572.	3.3	3
25	Circulating Myeloperoxidase (MPO)-DNA complexes as marker for Neutrophil Extracellular Traps (NETs) levels and the association with cardiovascular risk factors in the general population. PLoS ONE, 2021, 16, e0253698.	2.5	18
26	Endothelial Dysfunction, Atherosclerosis, and Increase of von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine. Thrombosis and Haemostasis, 2021, 121, 676-686.	3.4	11
27	Automated Fiber Diameter and Porosity Measurements of Plasma Clots in Scanning Electron Microscopy Images. Biomolecules, 2021, 11, 1536.	4.0	9
28	Detectable A Disintegrin and Metalloproteinase With Thrombospondin Motifs-1 in Serum Is Associated With Adverse Outcome in Pediatric Sepsis. , 2021, 3, e0569.		0
29	Does Fibrin Structure Contribute to the Increased Risk of Thrombosis in COVID-19 ICU Patients?. Blood, 2021, 138, 3208-3208.	1.4	3
30	Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 554-569.	2.4	61
31	Effects of Diabetes Mellitus on Fibrin Clot Structure and Mechanics in a Model of Acute Neutrophil Extracellular Traps (NETs) Formation. International Journal of Molecular Sciences, 2020, 21, 7107.	4.1	14
32	A Mendelian randomization of ϵ^2 and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke. Blood, 2020, 136, 3062-3069.	1.4	25
33	System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings. Blood Coagulation and Fibrinolysis, 2020, 31, 459-468.	1.0	5
34	Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery. Clinical Obesity, 2020, 10, e12397.	2.0	2
35	Deciphering the coagulation profile through the dynamics of thrombin activity. Scientific Reports, 2020, 10, 12544.	3.3	16
36	FIBTEM clot firmness parameters correlate well with the fibrinogen concentration measured by the Clauss assay in patients and healthy subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 600-605.	1.2	17

#	ARTICLE	IF	CITATIONS
37	ADAMTS α 13 and bleeding phenotype in von Willebrand disease. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1331-1339.	2.3	3
38	Performance of factor IX extended half-life product measurements in external quality control assessment programs. Journal of Thrombosis and Haemostasis, 2020, 18, 1874-1883.	3.8	8
39	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1056-1065.	3.4	5
40	The clinical effect of hemostatic resuscitation in traumatic hemorrhage; a before-after study. Journal of Critical Care, 2020, 56, 288-293.	2.2	5
41	Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. British Journal of Haematology, 2020, 190, 916-922.	2.5	15
42	Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. Blood, 2020, 136, 15-16.	1.4	0
43	Low Von Willebrand Factor: Cut-Off Value for Diagnosis and Risk Score to Predict Bleeding Incidence. Blood, 2020, 136, 18-19.	1.4	0
44	International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 1848-1859.	3.8	8
45	Targeting Tyrosine Phosphatases by 3-Bromopyruvate Overcomes Hyperactivation of Platelets from Gastrointestinal Cancer Patients. Journal of Clinical Medicine, 2019, 8, 936.	2.4	10
46	Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. Thrombosis and Haemostasis, 2019, 119, 1947-1955.	3.4	14
47	Prognostic Hemostasis Biomarkers in Acute Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 360-372.	2.4	37
48	Thyroid Function and Cardiovascular Disease: The Mediating Role of Coagulation Factors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3203-3212.	3.6	19
49	Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS ONE, 2019, 14, e0216222.	2.5	17
50	Comparison of thromboelastometry by ROTEM [®] Delta and ROTEM [®] Sigma in women with postpartum haemorrhage. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 32-38.	1.2	36
51	During the Early Stages of Staphylococcus aureus Biofilm Formation, Induced Neutrophil Extracellular Traps Are Degraded by Autologous Thermonuclease. Infection and Immunity, 2019, 87, .	2.2	22
52	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. Blood Advances, 2019, 3, 4147-4154.	5.2	12
53	Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. Circulation, 2019, 139, 620-635.	1.6	102
54	Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice?. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1235-1241.	2.3	7

#	ARTICLE	IF	CITATIONS
55	Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 91-99.	3.0	4
56	A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology. <i>Blood</i> , 2019, 133, 967-977.	1.4	34
57	Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme. <i>Haemophilia</i> , 2019, 25, 162-169.	2.1	20
58	VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD. <i>Blood</i> , 2019, 134, 1116-1116.	1.4	0
59	Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. <i>Blood Advances</i> , 2018, 2, 2433-2442.	5.2	35
60	High-Resolution Imaging of Interaction Between Thrombus and Stent Retriever in Patients With Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	13
61	Thrombophilia: Women-Specific Reference Ranges Can Prevent Misdiagnosis in Women. <i>journal of applied laboratory medicine, The</i> , 2018, 2, 737-745.	1.3	1
62	Staphylococcal Protein A Is a Key Factor in Neutrophil Extracellular Traps Formation. <i>Frontiers in Immunology</i> , 2018, 9, 165.	4.8	28
63	Prolonged Prothrombin Time After Discontinuing Vitamin K Antagonist. <i>Clinical Chemistry</i> , 2017, 63, 1442-1444.	3.2	1
64	ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study. <i>Diabetologia</i> , 2017, 60, 280-286.	6.3	23
65	Pitfalls in the diagnosis of hemophilia severity: What to do?. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26276.	1.5	2
66	In vitro induction of NETosis: Comprehensive live imaging comparison and systematic review. <i>PLoS ONE</i> , 2017, 12, e0176472.	2.5	158
67	Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study. <i>PLoS ONE</i> , 2017, 12, e0167742.	2.5	29
68	Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications. <i>Clinical Chemistry</i> , 2016, 62, 1639-1646.	3.2	37
69	PLA013: Von Willebrand Factor and the Risk of Dementia: A Population-Based Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P404.	0.8	1
70	Individualized Angiotensin-Converting Enzyme (ACE) Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model. <i>Journal of the American Heart Association</i> , 2016, 5, e002688.	3.7	16
71	Von Willebrand Factor, ADAMTS13, and the Risk of Mortality. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2446-2451.	2.4	56
72	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. <i>Human Molecular Genetics</i> , 2016, 25, 358-370.	2.9	73

#	ARTICLE	IF	CITATIONS
73	Elevated Levels of Circulating Nucleosomes Are Not Associated with Venous Thrombosis or Neutrophil Activation in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 274-274.	1.4	2
74	Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. <i>Blood</i> , 2015, 126, e19-e29.	1.4	55
75	Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. <i>Blood</i> , 2015, 126, 2739-2746.	1.4	125
76	Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. <i>Thrombosis and Haemostasis</i> , 2015, 113, 577-584.	3.4	35
77	Diet and haemostasis – A comprehensive overview. <i>Blood Reviews</i> , 2015, 29, 231-241.	5.7	23
78	von Willebrand Factor is elevated in HIV patients with a history of thrombosis. <i>Frontiers in Microbiology</i> , 2015, 6, 180.	3.5	23
79	Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity. <i>Blood</i> , 2015, 125, 3949-3955.	1.4	24
80	Specific Effects of Fibrinogen and the β A and β 2-Chain Fibrinogen Variants on Angiogenesis and Wound Healing. <i>Tissue Engineering - Part A</i> , 2015, 21, 106-114.	3.1	8
81	Performance Related Factors Are the Main Determinants of the von Willebrand Factor Response to Exhaustive Physical Exercise. <i>PLoS ONE</i> , 2014, 9, e91687.	2.5	22
82	No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects. <i>PLoS ONE</i> , 2014, 9, e111156.	2.5	8
83	Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. <i>Blood Reviews</i> , 2014, 28, 167-178.	5.7	115
84	Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study. <i>Blood</i> , 2014, 124, 113-113.	1.4	1
85	Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. <i>Atherosclerosis</i> , 2013, 230, 210-215.	0.8	34
86	Biological variation in tPA-induced plasma clot lysis time. <i>Thrombosis and Haemostasis</i> , 2012, 108, 640-646.	3.4	20
87	Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 485-493.	2.4	54
88	β 2 TM /total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2011, 105, 430-434.	3.4	22
89	Thrombophilia and Pre-Eclampsia. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 106-110.	2.7	15
90	Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 243-251.	3.4	23

#	ARTICLE	IF	CITATIONS
91	Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor. <i>Circulation</i> , 2010, 121, 1382-1392.	1.6	311
92	Nuclear Receptor Nurr1 Is Expressed In and Is Associated With Human Restenosis and Inhibits Vascular Lesion Formation In Mice Involving Inhibition of Smooth Muscle Cell Proliferation and Inflammation. <i>Circulation</i> , 2010, 121, 2023-2032.	1.6	46
93	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2010, 31, 1854-1864.	2.2	70
94	High von Willebrand Factor Levels Increase the Risk of Stroke. <i>Stroke</i> , 2010, 41, 2151-2156.	2.0	135
95	JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis. <i>Blood</i> , 2010, 116, 4212-4212.	1.4	4
96	Fibrinogen $\hat{3}$ ' In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study. <i>Blood</i> , 2010, 116, 4213-4213.	1.4	0
97	Metabolic Background Determines the Importance of NOS3 Polymorphisms in Restenosis after Percutaneous Coronary Intervention: A Study in Patients with and without the Metabolic Syndrome. <i>Disease Markers</i> , 2009, 26, 75-83.	1.3	6
98	Effects of Ambient Air Pollution on Hemostasis and Inflammation. <i>Environmental Health Perspectives</i> , 2009, 117, 995-1001.	6.0	90
99	Association of Novel Genetic Loci With Circulating Fibrinogen Levels. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 125-133.	5.1	86
100	Haplotypes of the <i>NR4A2/NURR1</i> gene and cardiovascular disease: The Rotterdam Study. <i>Human Mutation</i> , 2009, 30, 417-423.	2.5	13
101	Elevated fibrinogen $\hat{3}$ ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. <i>Blood</i> , 2009, 114, 4603-4604.	1.4	29
102	Fibrinogen $\hat{3}$ in Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1033-1035.	2.0	62
103	Microparticle-Associated Tissue Factor Activity and Venous Thrombosis in Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1812-1812.	1.4	0
104	Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. <i>Thrombosis and Haemostasis</i> , 2007, 97, 234-9.	3.4	3
105	High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke. <i>Stroke</i> , 2006, 37, 2672-2677.	2.0	219
106	Estrogen receptor 1 haplotype does not regulate oral contraceptive-induced changes in haemostasis and inflammation risk factors for venous and arterial thrombosis. <i>Human Reproduction</i> , 2006, 21, 1473-1476.	0.9	5
107	Fibrinogen heterogeneity: inherited and noninherited. <i>Current Opinion in Hematology</i> , 2005, 12, 377-383.	2.5	49
108	Genetic Influence on Inflammation Variables in the Elderly. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2168-2173.	2.4	96

#	ARTICLE	IF	CITATIONS
109	C-reactive protein as a risk factor versus risk marker. <i>Current Opinion in Lipidology</i> , 2004, 15, 651-657.	2.7	45
110	Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. <i>Atherosclerosis</i> , 1996, 121, 185-191.	0.8	119